X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Price:
74.76
CNY
-0.32%
Market Cap:
30.4B
CNY
Balance Sheet
Balance Sheet Decomposition
Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co Ltd
| Current Assets | 1.8B |
| Cash & Short-Term Investments | 651.5m |
| Receivables | 832.3m |
| Other Current Assets | 343.4m |
| Non-Current Assets | 1.2B |
| Long-Term Investments | 56.8m |
| PP&E | 703.7m |
| Intangibles | 379.7m |
| Other Non-Current Assets | 83.1m |
Balance Sheet
Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co Ltd
Currency: CNY
Millions
Annual
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
135
|
84
|
145
|
206
|
197
|
285
|
301
|
413
|
362
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
285
|
301
|
413
|
362
|
|
| Cash Equivalents |
135
|
84
|
145
|
206
|
197
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
268
|
196
|
271
|
257
|
290
|
|
| Total Receivables |
135
|
170
|
170
|
157
|
197
|
229
|
243
|
460
|
832
|
|
| Accounts Receivables |
122
|
150
|
111
|
124
|
163
|
186
|
217
|
438
|
771
|
|
| Other Receivables |
13
|
20
|
58
|
33
|
34
|
42
|
26
|
22
|
61
|
|
| Inventory |
31
|
41
|
55
|
71
|
100
|
116
|
130
|
187
|
264
|
|
| Other Current Assets |
2
|
1
|
4
|
12
|
11
|
8
|
11
|
24
|
80
|
|
| Total Current Assets |
302
|
295
|
374
|
445
|
773
|
834
|
956
|
1 340
|
1 827
|
|
| PP&E Net |
86
|
77
|
75
|
99
|
143
|
238
|
408
|
542
|
704
|
|
| PP&E Gross |
86
|
77
|
75
|
99
|
143
|
238
|
408
|
542
|
704
|
|
| Accumulated Depreciation |
98
|
110
|
122
|
135
|
142
|
147
|
169
|
195
|
228
|
|
| Intangible Assets |
243
|
253
|
231
|
219
|
250
|
310
|
342
|
353
|
380
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
37
|
57
|
|
| Other Long-Term Assets |
12
|
12
|
28
|
27
|
28
|
42
|
64
|
84
|
83
|
|
| Total Assets |
643
N/A
|
637
-1%
|
708
+11%
|
790
+12%
|
1 193
+51%
|
1 424
+19%
|
1 770
+24%
|
2 356
+33%
|
3 050
+29%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
4
|
3
|
10
|
20
|
19
|
39
|
97
|
41
|
60
|
|
| Accrued Liabilities |
28
|
27
|
31
|
39
|
49
|
76
|
113
|
244
|
231
|
|
| Short-Term Debt |
85
|
80
|
70
|
60
|
19
|
10
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
0
|
0
|
0
|
0
|
6
|
4
|
4
|
6
|
|
| Other Current Liabilities |
13
|
8
|
19
|
32
|
28
|
46
|
53
|
115
|
123
|
|
| Total Current Liabilities |
132
|
119
|
130
|
151
|
115
|
177
|
268
|
404
|
421
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
9
|
6
|
4
|
3
|
|
| Deferred Income Tax |
0
|
0
|
0
|
1
|
3
|
6
|
15
|
0
|
1
|
|
| Other Liabilities |
32
|
35
|
79
|
74
|
74
|
71
|
74
|
72
|
72
|
|
| Total Liabilities |
165
N/A
|
154
-6%
|
209
+35%
|
226
+9%
|
192
-15%
|
263
+37%
|
362
+38%
|
480
+32%
|
497
+4%
|
|
| Equity | ||||||||||
| Common Stock |
360
|
360
|
360
|
360
|
407
|
407
|
407
|
407
|
407
|
|
| Retained Earnings |
5
|
10
|
26
|
90
|
197
|
357
|
604
|
1 073
|
1 733
|
|
| Additional Paid In Capital |
113
|
113
|
113
|
113
|
397
|
397
|
397
|
397
|
413
|
|
| Total Equity |
478
N/A
|
483
+1%
|
499
+3%
|
564
+13%
|
1 000
+78%
|
1 161
+16%
|
1 408
+21%
|
1 876
+33%
|
2 553
+36%
|
|
| Total Liabilities & Equity |
643
N/A
|
637
-1%
|
708
+11%
|
790
+12%
|
1 193
+51%
|
1 424
+19%
|
1 770
+24%
|
2 356
+33%
|
3 050
+29%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
360
|
360
|
360
|
360
|
407
|
407
|
407
|
407
|
407
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
